The Indoor Lab Expands Executive Team, Welcomes Greg Moya as Chief Operating Officer
Greg Moya
SAN JUAN CAPISTRANO, Calif., May 06, 2025--(BUSINESS WIRE)--The Indoor Lab, the world's leading agnostic LiDAR perception software company, today announced the expansion of its leadership team with the appointment of Greg Moya, former Chief Technology Officer of Computer Vision at Dell Technologies, as its new Chief Operating Officer (COO).
Greg Moya brings decades of experience in enterprise-grade computer vision, edge computing, and AI-driven operational systems. At Dell, he led the strategy and development of cutting-edge computer vision platforms, helping to deploy intelligent infrastructure across a global customer base. His expertise will now help drive The Indoor Lab's aggressive growth strategy as it scales its platform across cities, airports, and other critical infrastructures.
"Greg's visionary leadership and deep technical expertise in scalable perception platforms make him the perfect addition to our team," said Patrick Blattner, CEO and Founder of The Indoor Lab. "As we prepare for a major expansion phase, his operational insight will be key to accelerating our mission of creating central nervous systems for the world's most vital spaces."
The Indoor Lab is pioneering the use of agnostic LiDAR perception software to enable real-time awareness and automation. By acting as the "central nervous system" for airports, cities, and other high-traffic environments, the company is redefining how organizations approach safety, efficiency, and intelligent infrastructure.
"I'm thrilled to join The Indoor Lab at such a pivotal time," said Greg Moya, new COO. "The opportunity to help shape the future of real-time perception and play a role in revolutionizing public infrastructure is truly exciting."
This leadership expansion comes at a moment when demand for accurate, privacy-safe, and scalable perception systems is surging. The Indoor Lab's patented solutions are already in use at major international airports and urban environments, with plans to expand across new industries and geographies in 2025 and beyond.
About The Indoor Lab
The Indoor Lab is the leading LiDAR perception software company developing real-time "central nervous systems" for cities, airports, and critical infrastructure to enhance safety, efficiency, and operational awareness. Our flagship enterprise platform, OVERWATCH, is recognized as the gold standard across aviation, urban environments, government agencies, and entertainment venues. With a fully agnostic approach to lidar sensor integration and a powerful analytics AI engine, OVERWATCH delivers unparalleled visibility, automation, and decision intelligence for physical spaces.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
WIRED
15 hours ago
- WIRED
The Dell 14 Plus Tries Its Best to Reset Dell's Laptops
Dell is in the middle of a transition. It has a new logo, and a new simplified approach to branding. The Dell 14 Plus is among the first laptop to launch to test the waters in this new era, which is seeing the end of subbrands like XPS and Inspiron. While the more exciting XPS replacement is still to come, the Dell 14 Plus has arrived to step into the shoes of the old Inspiron Plus laptops. While it's far from the most exciting laptop in the world, it offers a solid balance of quality and value, if only it had more configuration options available to properly classify it as a cheap laptop. Dell On The Shell Photograph: Luke Larsen The Dell 14 Plus isn't what I'd call a pretty laptop. But I don't think it's trying to be. Instead, it's trying to be inoffensive. In the past, that might have meant a plastic, black shell. These days, it means a silver chassis with as few distractions or ornaments as possible. The Dell 14 Plus succeeds at doing that. More importantly, the laptop feels quite sturdy in the hand. The lid has absolutely zero give, likely because of how tightly wound the hinge is. You can't open it with one finger though—in fact, there isn't even a lip on the lid for your finger. That lid is thicker than normal, too, despite the device being just 0.67 inches thick. That's not thin compared to a MacBook Air, no, but it's thin enough to feel modern for a laptop of this price. It also allows for enough room to squeeze in some legacy ports, including USB-A and HDMI. That's in addition to the two USB-C ports and the headphone jack. My only complaint is that both USB-C ports are on the left side, meaning it's the only side you can charge from. One of the things that keeps the Dell 14 Plus from feeling like a more premium laptop is the screen. It has some thick plastic bezels, and it uses a heavy-handed matte finish. While that helps for deflecting glare, it cheapens the look of the display, making it appear dimmer and more saturated. That's too bad too, since the screen itself is a solid one. It's a surprisingly well-calibrated IPS panel with decent color coverage. According to my testing, it tops out at 332 nits of brightness, which won't blow your socks off, but won't detract too much from the experience. I should mention that Dell offers a better display option on its 2-in-1 models. It's a glossy Mini-LED display, though it's not currently available from what I can see. The Dell 14 Plus has a serviceable keyboard and touchpad. Upon receiving the unit, I was concerned about the quality of the touchpad, as its an aspect of mid-tier laptops that tends to get compromised. The touchpad isn't perfect—the surface isn't as smooth as I'd like. But I'm happy to report that this touchpad feels responsive, and the click mechanism isn't overly loud. Limited Options Photograph: Luke Larsen The Dell 14 Plus has just single processor options, the Intel Core Ultra 7 256V. This is Intel's modern, efficient CPU that delivers a solid jump in battery life over previous generations. I've tested this chip a number of times already, and the Dell 14 Plus handles it just fine. The Dell 14 Plus even does a job of staying relatively cool and quiet. This isn't the kind of laptop you buy for running heavy applications or games, but for the school, office work, or light content creation, the Dell 14 Plus has plenty of muscle.
